Numerical Investigation of the Fractional Oscillation Equations under the Context of Variable Order Caputo Fractional Derivative via Fractional Order Bernstein Wavelets

This article describes an approximation technique based on fractional order Bernstein wavelets for the numerical simulations of fractional oscillation equations under variable order, and the fractional order Bernstein wavelets are derived by means of fractional Bernstein polynomials. The oscillation equation describes electrical circuits and exhibits a wide range of nonlinear dynamical behaviors. The proposed variable order model is of current interest in a lot of application areas in engineering and applied sciences. The purpose of this study is to analyze the behavior of the fractional force-free and forced oscillation equations under the variable-order fractional operator. The basic idea behind using the approximation technique is that it converts the proposed model into non-linear algebraic equations with the help of collocation nodes for easy computation. Different cases of the proposed model are examined under the selected variable order parameters for the first time in order to show the precision and performance of the mentioned scheme. The dynamic behavior and results are presented via tables and graphs to ensure the validity of the mentioned scheme. Further, the behavior of the obtained solutions for the variable order is also depicted. From the calculated results, it is observed that the mentioned scheme is extremely simple and efficient for examining the behavior of nonlinear random (constant or variable) order fractional models occurring in engineering and science.Comment: This is a preprint of a paper whose final and definite form is published Open Access in 'Mathematics' at [http://dx.doi.org/10.3390/math11112503

CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis

Active vaccination can be effective as a post-exposure prophylaxis, but the rapidity of the immune response induced, relative to the incubation time of the pathogen, is critical. We show here that CD40mAb conjugated to antigen induces a more rapid specific antibody response than currently used immunological adjuvants, alum and monophosphoryl lipid A™

Modeling of the Resonant Inverter for Wireless Power Transfer Systems Using the Novel MVLT Method

Wireless power transfer (WPT) is a power transfer technique widely used in many industrial applications, medical applications, and electric vehicles (EVs). This paper deals with the dynamic modeling of the resonant inverter employed in the WPT systems for EVs. To this end, the Generalized State-Space Averaging and the Laplace Phasor Transform techniques have been the flagship methods employed so far. In this paper, the modeling of the resonant inverter is accomplished by using the novel Modulated Variable Laplace Transform (MVLT) method. Firstly, the MVLT technique is discussed in detail, and then it is applied to model a study-case resonant inverter. Finally, a study-case resonant inverter is developed and utilized to validate the theoretical results with MATLAB/Simulink

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD) and recommended phase 2 dose of E7046.Methods This first-in-human study enrolled 30 patients with advanced tumors of cancer types associated with high levels of myeloid infiltrates. E7046 was administered orally once-daily in sequential escalating dose cohorts (125, 250, 500, and 750 mg) with ≥6 patients per cohort. Tumor assessments were performed every 6 weeks. Paired tumor biopsies and blood samples, before and on treatment, were collected for pharmacokinetic and pharmacodynamic characterization of the treatment.Results No dose-limiting toxicities were observed, and the MTD was not reached. E7046 had an elimination half-life (t1/2) of 12 hours, and drug exposure increased dose-dependently from 125 to 500 mg. Target modulation by E7046 was supported by changes in genes downstream of EP4 with concurrent enhanced antitumoral immune responses. A best response of stable disease (per irRECIST) was reported in 23% of patients treated with E7046 (n=30) (125 mg: n=2; 250 mg: n=2; 750 mg: n=3). Over half (4/7) of the patients with stable disease had treatment duration of 18 weeks or more, and three patients (3/15; 20%) achieved metabolic responses.Conclusions In this first-in-human study, E7046 administered orally once daily demonstrated manageable tolerability, immunomodulatory effects, and a best response of stable disease (≥18 weeks) in several heavily pretreated patients with advanced malignancies. The 250 and 500 mg doses are proposed for further development in the combination setting.Trial registration number NCT02540291